麝香保心丸联合常规西药对50例冠心病心绞痛患者的疗效及血清IL-6、hs-CRP的影响

摘要

Objective:To observe and evaluate the effect of Shexiangbaoxin pills combined with conventional western medicine in the treatment of patients with coronary heart disease and angina pectoris and on serum IL-6, hs-CRP, blood lipid levels and E-selectin, SICAM-1, SVCAM-1. Methods:One hundred patients with coronary heart disease and angina pectoris in our hospital from January, 2013 to June, 2015 were randomly selected and divided into a control group and an observation group with 50 patients each. The control group was treated with conventional western medicine including isosorbide dinitrate tablets, simvastatin, aspirin for 1 month and the observation group was additionally treated with Shexiangbaoxin pills for 1 month on the basis of the control group. Results:The total efifciency was signiifcantly higher in the observation group (92%) than the control group (66%) (P<0.01). The levels of hs-CRP, IL-6, blood lipid (TG, TC, LDL-C), E-selectin, SICAM-1and SVCAM-1 were signiifcantly lower after treatment than before and in the observation group than the control group (P<0.01). Conclusion:Shexiangbaoxin pills combined with conventional western medicine in the treatment of patients with coronary heart disease and angina pectoris has an obvious curative effect and can effectively reduce the indicators mentioned above and relieve the inlfammation reaction and the damage to endothelial cells and improve the function of endothelial cells, reverse the vascular remodeling and protect blood vessels.%目的：观察和评估麝香保心丸联合常规西药对冠心病心绞痛患者的疗效及血清IL-6、hs-CRP，血脂水平和E-选择素，SICAM-1、SVCAM-1等的影响。方法：随机选取我院2013年1月—2015年6月收治的冠心病心绞痛患者100例，按治疗方式的不同分为观察组和对照组各50例，对照组采用硝酸异山梨酯片、辛伐他汀、阿司匹林等常规西药治疗。观察组在常规西药治疗的基础上，加服麝香保心丸。结果：观察组患者治疗的总有效率为92.00%，明显高于对照组患者的66.00%（P<0.01）；两组患者治疗后IL-6、hs-CRP水平明显低于治疗前，且观察组患者治疗后IL-6、hs-CRP水平明显低于对照组患者（P<0.01）；两组患者治疗后血脂水平（TG、TC、LDL-C）均明显低于治疗前，且观察组患者治疗后的血脂水平（TG、TC、LDL-C）均明显低于对照组患者（P<0.01）；两组患者治疗后E-选择素，SICAM-1、SVCAM-1水平明显低于治疗前，且观察组患者治疗后E-选择素，SICAM-1、SVCAM-1水平明显低于对照组患者（P<0.01）。结论：麝香保心丸联合常规西药对冠心病心绞痛患者的疗效显著，能有效降低患者的IL-6、hs-CRP水平，减轻患者的炎症反应，亦能降低患者的血脂水平和E-选择素，SICAM-1、SVCAM-1水平，减轻内皮细胞的损坏，改善内皮细胞功能，逆转血管重塑，保护血管。